HeliTrax® for Healthcare Professionals

The enhanced HeliTrax® System

A closer connection to hemophilia A patients’ needs

The state-of-the-art design of the HeliTrax System helps strengthen communication between you and your patients to better manage their treatment together. With new features and enhancements, the HeliTrax System makes it even easier for you to get a clearer picture of your hemophilia A patients’ treatment needs and motivate them to stay on track.

Stay in touch during bleeding episodes

You can keep informed of your patients’ hemophilia A symptoms (i.e., bleeding events) anywhere and at any time with the HeliTrax System:

  • Allows for rapid assessment of emergency bleeding events through the built-in camera feature
  • Sends a high-priority message directly to the treatment team during emergency bleeding event situations
  • Describes the specifics of a bleeding event in detail, complete with location, symptoms, and picture
  • Stores information for your patient’s entire family

A comprehensive view of patient progress

The HeliTrax System enables you to evaluate how your hemophilia A patients are responding to and coping with treatment:

  • Track medication usage, inventory, bleeding events, and follow-up
  • Access patient data before and between visits to readily anticipate complications or concerns
  • View hemophilia A symptoms, such as bleeding events, to determine their severity
  • Maintain records of other treatments patients are taking

Patient-friendly features to help keep them on track

Patients can put you in touch with their treatment needs through their handheld device or web interface wherever a wireless internet connection, or computer with online access is available. The HeliTrax System allows them to:

  • Analyze, organize, and print treatment data
  • Review their progress, which may assist with treatment compliance
  • Keep you in touch with their progress with the Web interface, even when they don’t have their handheld electronic diary

“HeliTrax allows us to receive real-time reporting of bleeds in our patients. Previously, we reviewed that history every 6 months at the comprehensive visit. This gives us the ability to intervene sooner when we determine a patient has developed a target joint.” — RN, MS, at the University of Virginia Children’s Hospital

Fully compatible with WebTrackerTM

How the HeliTrax® System can make a difference to the treatment team

Patient adherence to treatment is very important to the treatment team. The enhanced HeliTrax System makes a difference by helping hemophilia A patients comply with treatment both for acute or episodic bleeds, and for prophylaxis. The HeliTrax System also simplifies tracking of patient needs and makes data management more convenient. With the HeliTrax System,the treatment team can:

  • Save time by eliminating paperwork and by having only high-priority messages directed to them
  • Reduce the risk of documentation and transcription errors
  • Provide JCAHO-compliant progress reports for patients’ medical records
  • Report patient data to the Centers for Disease Control and Prevention (CDC) with a system that is fully compatible with Lab TrackerTM and NEW WebTrackerTM
  • Assign a new individual log-in and user name for each healthcare provider on the treatment team
  • Tracking patient information with the HeliTrax System

The graph on the left shows the amount of product infused for prophylaxis during a specific time period; the graphic on the right shows the list of messages a physician and their treatment team can review regarding their patient’s treatment (sample list shows occurrence of 2 different bleeds and incorrect prophylaxis infusions).

To speak with a live representative about the HeliTrax System, call the HeliTrax System helpdesk at 1-800-598-6445.

Next: Patient Programs and Services »

Important Safety Information

Helixate® FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A. Helixate® FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no preexisting joint damage.

The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to antihemophilic factor. The most common adverse reactions observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections.

Helixate® FS is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins.

Please see the full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.